CZ Veterinaria, in its 25th Anniversary, changes its brand to CZ Vaccines

The change of brand coincides with the 25th anniversary of the biotech company’s founding. The company is a world leader in the production of mycobacteria, with an annual manufacturing capacity of 150 million doses of tuberculin, and leads the supply of vaccines for bluetongue disease in Europe.

The company's CEO, Andrés Fernández Álvarez-Santullano, points out that the company, responds to the "new challenges for prevention" by renaming CZ Veterinaria as CZ Vaccines. "Twenty-five years later we are bigger and our field of action is wider; we have a more global perspective and we want a brand that represents this growth. A brand that does justice to our essence, biotechnology and, ultimately, prevention through vaccines," he explains.